LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

β-lapachone: a promising anticancer agent with a unique NQO1 specific apoptosis in pancreatic cancer.

Photo by nci from unsplash

Cancer, one of the major health problems all over the world, requires more competent drugs for clinical use. One recent possible chemotherapeutic drug under research is β-lapachone. β-lapachone (1,2-naphthoquinone) has… Click to show full abstract

Cancer, one of the major health problems all over the world, requires more competent drugs for clinical use. One recent possible chemotherapeutic drug under research is β-lapachone. β-lapachone (1,2-naphthoquinone) has promising activity against those tumors which are showing raised levels of Nicotinamide di-phosphate Quinone Oxidoreductases-1 (NQO1). NQO1 is found to be up-regulated in pancreatic tumor cells, and thus β-lapachone could generate cytotoxicity in various cancers like pancreatic tumors. β-lapachone harborage independent growth and clonogenic cell survival in agar. The cell-killing effects of β-lapachone can be stopped by using dicumarol, an inhibitor of NAD(P)H Quinone Oxidoreductases-1. In previously established pancreatic cancer xenografts in mice, β-lapachone inhibited the tumor growth when given orally rather than when combined with cyclodextrin to improve its bioavailability.

Keywords: anticancer agent; pancreatic cancer; lapachone promising; promising anticancer; lapachone; cancer

Journal Title: Current cancer drug targets
Year Published: 2022

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.